TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) is now available.
Shanghai Haohai Biological Technology Co., Ltd. reported a decrease in revenue and profit for the six-month period ending June 30, 2025, compared to the same period in 2024. Revenue fell by approximately 7.48% to RMB1,292.64 million, while profit attributable to ordinary equity holders decreased by 10.29% to RMB211.07 million. Despite these declines, the company maintained its interim dividend at RMB0.40 per share. The decrease in R&D expenses by 21.53% and a slight improvement in other income and gains were notable financial movements during the period.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. is a joint stock company incorporated in China, operating in the biotechnology sector. The company focuses on the development and production of biological products and technologies.
Average Trading Volume: 724,660
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$13.11B
For a thorough assessment of 6826 stock, go to TipRanks’ Stock Analysis page.